Canadian real-world study of aripiprazole LAI in schizophrenia

 

POSTER DISCUSSION

Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, Florida, May 29 – June 1, 2018

The first Canadian naturalistic study in patients with schizophrenia has reported high rates of remission rates and low rates of relapse with long-acting aripiprazole over a one-year period (Oluboka et al. ASCP 2018; abstract).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page